314 related articles for article (PubMed ID: 21172030)
1. Treatment of dyslipidemia in patients with type 2 diabetes.
Vijayaraghavan K
Lipids Health Dis; 2010 Dec; 9():144. PubMed ID: 21172030
[TBL] [Abstract][Full Text] [Related]
2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
3. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
[TBL] [Abstract][Full Text] [Related]
4. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management.
Chehade JM; Gladysz M; Mooradian AD
Drugs; 2013 Mar; 73(4):327-39. PubMed ID: 23479408
[TBL] [Abstract][Full Text] [Related]
5. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
6. New insights into the pathophysiology of dyslipidemia in type 2 diabetes.
Taskinen MR; Borén J
Atherosclerosis; 2015 Apr; 239(2):483-95. PubMed ID: 25706066
[TBL] [Abstract][Full Text] [Related]
7. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
8. Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials.
Farmer JA
Curr Atheroscler Rep; 2007 Aug; 9(2):162-8. PubMed ID: 17877926
[TBL] [Abstract][Full Text] [Related]
9. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Cardiovasc Diabetol; 2006 Sep; 5():20. PubMed ID: 17002798
[TBL] [Abstract][Full Text] [Related]
10. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
[TBL] [Abstract][Full Text] [Related]
11. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
Soska V
Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
[TBL] [Abstract][Full Text] [Related]
12. Combination lipid therapy in type 2 diabetes mellitus.
Vergès B
Expert Opin Pharmacother; 2011 Jun; 12(9):1393-403. PubMed ID: 21323502
[TBL] [Abstract][Full Text] [Related]
13. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
[TBL] [Abstract][Full Text] [Related]
14. Managing diabetic dyslipidemia: beyond statin therapy.
Neeli H; Gadi R; Rader DJ
Curr Diab Rep; 2009 Feb; 9(1):11-7. PubMed ID: 19192419
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
[TBL] [Abstract][Full Text] [Related]
16. Future perspectives of the pharmacological management of diabetic dyslipidemia.
Patti AM; Giglio RV; Papanas N; Rizzo M; Rizvi AA
Expert Rev Clin Pharmacol; 2019 Feb; 12(2):129-143. PubMed ID: 30644763
[TBL] [Abstract][Full Text] [Related]
17. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones.
Florkowski CM
Am J Cardiovasc Drugs; 2002; 2(1):15-21. PubMed ID: 14727995
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic treatment of type 2 diabetic dyslipidemia.
Moon YS; Kashyap ML
Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
[TBL] [Abstract][Full Text] [Related]
19. Insulin resistance syndrome and type 2 diabetes mellitus.
Erkelens DW
Am J Cardiol; 2001 Oct; 88(7B):38J-42J. PubMed ID: 11595198
[TBL] [Abstract][Full Text] [Related]
20. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
